Martora Fabrizio, Scalvenzi Massimiliano, Battista Teresa, Fornaro Luigi, Potestio Luca, Ruggiero Angelo, Megna Matteo
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Clin Cosmet Investig Dermatol. 2023 Sep 18;16:2525-2536. doi: 10.2147/CCID.S418748. eCollection 2023.
The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, the only biologic drugs approved for HS are adalimumab, an anti-tumor necrosis factor (TNF)-α drug, authorized in 2015, and secukinumab, recently licensed. The management of this condition is challenging as the available treatments show variable results, and the course of the condition is often chronic-recurrent; therefore, it will be necessary for the future to identify new therapeutic targets for HS. In recent years, studies have focused on the development towards new therapeutic targets. The purpose of our review was to perform a comprehensive literature review of real-life data on anti-IL23 (guselkumab, tildrakizumab, and risankizumab) in HS to summarize the existing evidence on the efficacy and safety of these drugs. We selected 64 articles, among which 32 had the characteristics that we were looking for in our review. To date, the positive data expressed in real-life experiences contrast with the three existing Phase 2 studies conducted so far, where it seems that these drugs may be useful only for a subgroup of patients with HS whose features need to be elucidated. Data from Phase 3 studies and other real-life experiences, perhaps more detailed and with higher numbers, will certainly be needed to fully understand the efficacy and safety of this class of drugs.
化脓性汗腺炎（HS）的治疗一直是皮肤科医生面临的一项真正挑战；迄今为止，仅有的被批准用于HS的生物药物是2015年获批的抗肿瘤坏死因子（TNF）-α药物阿达木单抗，以及最近获得许可的司库奇尤单抗。由于现有治疗效果各异，且该病病程往往呈慢性复发性，因此对这种疾病的管理颇具挑战性；所以，未来有必要确定HS的新治疗靶点。近年来，研究聚焦于朝着新治疗靶点的发展。我们综述的目的是对HS中抗IL-23（古塞库单抗、替拉珠单抗和瑞莎珠单抗）的真实世界数据进行全面的文献综述，以总结这些药物疗效和安全性的现有证据。我们筛选了64篇文章，其中32篇具有我们在综述中所寻求的特征。迄今为止，真实世界经验中所呈现的阳性数据与目前已开展的三项2期研究形成对比，在这些研究中似乎这些药物可能仅对HS患者中的一个亚组有用，而该亚组患者的特征尚待阐明。肯定需要3期研究和其他或许更详尽且病例数更多的真实世界经验的数据，才能全面了解这类药物的疗效和安全性。
